Celyad Oncology SA
CLYYF
$0.25
-$0.10-28.57%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.62M | 2.63M | -2.09M | -1.93M | -1.48M |
| Total Depreciation and Amortization | -53.00K | -53.20K | 115.80K | 107.30K | 72.50K |
| Total Amortization of Deferred Charges | 34.30K | 34.50K | -- | -- | 45.30K |
| Total Other Non-Cash Items | -3.84M | -3.86M | 97.00K | 90.00K | -89.50K |
| Change in Net Operating Assets | -871.90K | -875.70K | 14.80K | 13.70K | -65.00K |
| Cash from Operations | -2.11M | -2.12M | -1.86M | -1.72M | -1.52M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | 1.75M | 1.76M | -- | -- | 8.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Investing | 1.75M | 1.76M | -- | -- | 8.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -26.50K | -26.50K | -36.50K | -36.50K | -42.00K |
| Issuance of Common Stock | 482.50K | 482.50K | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 309.00K | 309.00K | -31.50K | -31.50K | 446.00K |
| Cash from Financing | 890.50K | 894.40K | -77.20K | -71.60K | 430.70K |
| Foreign Exchange rate Adjustments | 3.50K | 3.50K | 600.00 | 500.00 | -2.10K |
| Miscellaneous Cash Flow Adjustments | 600.00 | 600.00 | -600.00 | -500.00 | 500.00 |
| Net Change in Cash | 534.30K | 536.60K | -1.94M | -1.79M | -1.08M |